secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2024-04-25T23:59:59+00:00
Accession:  0001104659-24-051517
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q1 sales up 9% to $15.8B; raises FY2024 sales and EPS guidance
--------------------------------------------------------------------

- GAAP EPS $1.87 (+68% YoY); Non-GAAP EPS $2.07 (+48% YoY). Sales $15.775B (+9%, +12% ex-FX).
- Keytruda sales grew 20% to $6.9B; Gardasil sales up 14% to $2.2B on strong China demand.
- Full-year 2024 sales outlook raised to $63.1-$64.3B; Non-GAAP EPS outlook raised to $8.53-$8.65.
- Received FDA approval for WINREVAIR (PAH); closed Harpoon acquisition with $656M charge.
- Proposed acquisition of Elanco's aqua business to broaden animal health portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465924051517/0001104659-24-051517-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465924051517/tm2412490d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-051517

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer